secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2026-11-02T12:15:10+00:00
Accession:  0001193125-26-442648
Event type: regulatory
Sentiment:  positive
Materiality: 0.92
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Inovio wins FDA accelerated approval of VOCERYQ, first U.S.-approved DNA medicine, for RRP
--------------------------------------------------------------------------------

- FDA granted accelerated approval for VOCERYQ (formerly INO-3107) to reduce frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).
- Pivotal RRP-001: 7 of 26 efficacy patients (27%, 95% CI 12-48%) had complete response — no surgical excision 12 months after treatment; median 4.5 prior surgeries.
- Inovio expects VOCERYQ to be orderable and shipping in about 60 days, with full field deployment in Q1 2027; Syneos Health engaged for commercial and medical field teams.
- Confirmatory study required: draft protocol due to FDA by end of 2026, final protocol alignment expected mid-2027; continued approval contingent on verifying clinical benefit.
- Inovio cites a prevalent U.S. RRP population of at least 25,000; VOCERYQ approved in combination with the CELLECTRA 5PSP delivery device.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526442648/0001193125-26-442648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312526442648/d150457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-442648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer